| AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma |
Abstract
|
|
Heather Cartwright & Smita Mishra |
|
| Bayer Augments Thrombosis Pipeline by Licensing ISIS-FXIRx from Isis Pharmaceuticals |
Abstract
pdf
|
|
Heather Cartwright & Rohit Khera |
|
| Teva Returns to M&A with US$3.5 B Auspex Pharma Purchase Before Making US$40 B Approach for Mylan |
Abstract
|
|
Heather Cartwright & Sayani Datta |
|
| Alexion to Acquire Synageva for US$8.4 B to Diversify its Rare Disease Portfolio |
Abstract
|
|
Heather Cartwright & Tridisha Goswami |
|
